Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to VP, Clinical Development with immediate effect.
Dr Thompson has more than 15 years’ experience in translational research and early clinical development. He joined Mission as Medical Director for CNS in 2016 from ONO Pharma UK, where he was Clinical Science Director.
Prior to this he worked at GlaxoSmithKline, where he led global project teams as Director of Discovery Medicine in Neurology, following previous roles in laboratory biomarker research and experimental medicine study leadership.
Dr Thompson holds an MBiochem from the University of Oxford and a PhD in Immuno and Cell Biology from UCL.
He is also a member of the British Pharmacological Society, Society for Neuroscience and American Academy of Neurology and is currently the Principal Investigator on a Target Validation award from the Michael J Fox Foundation.
Dr Anker Lundemose, Mission’s CEO, said: "Paul’s promotion reinforces our drug discovery and development expertise as we continue our mission to translate scientific advances in the DUB field into transformative therapies."
"He has already made a substantial contribution to the development of our internal pipeline. He will continue to play a pivotal role in driving the pre-clinical validation and prioritisation of our first-in-class compounds as we progress them towards clinical testing."
Dr Paul Thompson, newly appointed VP, Clinical Development, Mission Therapeutics, said: "This is an exciting opportunity to further influence and shape the company’s therapeutic programmes at the senior management level."
"I look forward to working with the team to continue improving our understanding of DUBs as therapeutic targets and their multiple potential applications to serious diseases with high unmet need, including fibrosis, rare mitochondrial disease and neurodegeneration."
